Mabwell(SH:688062) Ge Long Hui A P P·2025-11-30 07:47Core Viewpoint - Maiwei Biotech (688062.SH) has completed the Phase IIa clinical study of its innovative drug 9MW1911 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD), showing promising safety and efficacy results compared to placebo [1] Group 1: Clinical Study Results - The Phase IIa study involved 80 patients, with 20 in the placebo group [1] - All dosage groups of 9MW1911 demonstrated good safety and tolerability compared to the placebo [1] - The annualized rate of acute exacerbations of COPD decreased with increasing doses of 9MW1911 [1] Group 2: Efficacy Metrics - In the recommended Phase IIb dose (RP2D) study involving 30 patients, the annualized rate of acute exacerbations in moderate COPD patients was reduced by over 30% compared to the placebo group [1] - The annualized rate of severe acute exacerbations decreased by over 40% compared to the placebo group [1] - The proportion of patients experiencing severe acute exacerbations was significantly lower in the treatment group (13.3%) compared to the placebo group (35%) [1] Group 3: Future Developments - The company is actively advancing the Phase IIb clinical study of 9MW1911 for COPD indications [1]